Human GLUT5 specific inhibitors and methods of treatment
The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human GLUT5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of GLUT5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through GLUT5, including such disease states and conditions as GLUT5 deficiency syndrome, diabetes (type I and II), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others.
1. A method of therapeutically treating a disease state or condition which is mediated through GLUT5 in a patient in need, comprising administering to said patient a therapeutically effective amount of a composition comprising at least one compound according to the chemical structure;
or a Pharmaceutically acceptable salt or solvate thereof, wherein said disease state or condition is diabetes type I, diabetes type II or a metabolic disease.
2. The method according to claim 1 wherein said metabolic disease is metabolic syndrome or fatty liver disease.
3. The method according, to claim 1 comprising administering to said patient an additional bioactive agent selected from the group consisting of an additional agent for the treatment of diabetes I or II or metabolic syndrome, a cardiovascular agent, a statin or a mixture thereof.
4. The method according to claim 3 wherein said additional bioactive agent is insulin, metformin, glipizide, glimepiride, glyburide, bromocriptine, pioglitazone, acarbose, sitagliptin, netaglinide, colesevelam, chlorpropamide, exenatide, liriglutide, repaglinide, rosiglitazone, saxagliptin, linaglipton, canagliflozin, miglitol, tolbutamide, tolazamide, mifepristone, dapagliflozin, pramlintide, alogliptin, albiglutide, empagliflozin, dulaglutide or a mixture thereof.
5. The method according to claim 3 wherein said additional bioactive agent is an agent for hypertensive emergency, an agent for pulmonary hypertension, an aldosterone receptor antagonist, an angiotensin converting enzyme inhibitor, an angiotensin receptor blocker, an antiadrenergic agent, an antianginal agent, an antiarrhythmic agent, an anticholinergic chronotropic agent, an ACE inhibitor, a calcium channel blocking agent, a thiazide, a beta blocker, a potassium sparing diuretic, a beta-adrenergic blocker, a catecholamine, a diuretic, an inotropic agent, a vasodilator, a renin inhibitor, a sclerosing agent, a vasopressin antagonist, a vasopressor or a mixture thereof.
6. The method according to claim 1 wherein said compound is
or a pharmaceutically acceptable salt thereof.
7. The method according to claim 2 wherein said compound is MSNBA or a pharmaceutically acceptable salt thereof.
8. The method according to claim 3 wherein said compound is MSNBA or a pharmaceutically acceptable salt thereof.
9. The method according to claim 4 wherein said compound is MSNBA or a pharmaceutically acceptable salt thereof.
10. The method according to claim 5 wherein said compound is MSNBA or a pharmaceutically acceptable salt thereof.
11. The method according to claim 1 wherein said disease state or condition is diabetes type I or II.
12. The method according to claim 1 wherein said disease state or condition is a metabolic disease.
13. A method of therapeutically treating a disease state or condition which is mediated through GLUT5 in a patient in need, comprising administering to said patient a therapeutically effective amount of a composition comprising a compound according to the chemical structure:
or a pharmaceutically acceptable salt thereof, wherein said disease state or condition is diabetes type I, diabetes type II, or a metabolic disease.
14. The method according to claim 13 wherein said disease state is diabetes type I or diabetes type II.
15. The method according to claim 13 wherein said disease state is a metabolic disease.
16. The method according to claim 15 wherein said metabolic disease is metabolic syndrome or fatty liver disease.
17. The method according to claim 16 wherein said fatty liver disease is non-alcohol fatty liver disease.